Europe — EMA
Enhertu (Trastuzumab Deruxtecan)
Enhertu (Trastuzumab Deruxtecan) is an advanced intravenous medication used for targeted therapy. It combines a monoclonal antibody with a cytotoxic agent for p
Request sourcing
What is Trastuzumab Deruxtecan?
Enhertu (Trastuzumab Deruxtecan) is an advanced intravenous medication used for targeted therapy. It combines a monoclonal antibody with a cytotoxic agent for precise treatment.
What is Trastuzumab Deruxtecan used for?
Enhertu is primarily used in the treatment of certain types of cancer. It targets specific cells to deliver a cytotoxic payload, aiming to minimize damage to healthy tissues. This medication is often considered for patients who have limited treatment options.
What are the side effects of Trastuzumab Deruxtecan?
Enhertu may cause various side effects, including fatigue, nausea, and hair loss. Some patients might experience more severe reactions, such as low blood cell counts or liver issues. Always consult a healthcare provider for personalized advice.
What precautions apply to Trastuzumab Deruxtecan?
Enhertu should be handled with care, as it is intended for intravenous use only. It is crucial to follow the administration guidelines provided by healthcare professionals. Patients should be monitored regularly for any adverse reactions.
What does Trastuzumab Deruxtecan interact with?
Enhertu may interact with other medications, including those that affect the immune system or blood cell production. It is important to inform healthcare providers about all current medications to avoid potential interactions.
